STOCK TITAN

Oncternal Therapeutics, Inc. - ONCT STOCK NEWS

Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) is a clinical-stage biopharmaceutical company dedicated to developing innovative oncology therapies targeting cancers with significant unmet medical needs. The company's diverse product pipeline aims to address a wide range of malignancies, advancing novel therapeutic approaches with the potential to significantly improve patient outcomes.

One of Oncternal's flagship products is zilovertamab, a humanized monoclonal antibody that targets the receptor-tyrosine kinase-like orphan receptor 1 (ROR1). Currently in Phase 1/2 clinical trial, zilovertamab is being tested in combination with ibrutinib for mantle cell lymphoma and chronic lymphocytic leukemia, as well as in combination with paclitaxel for HER2-negative metastatic breast cancer.

Another key product in the pipeline is ONCT-216, a small molecule designed to inhibit ETS-family oncoproteins. ONCT-216 is undergoing Phase 1 trials to treat Ewing sarcoma, among other potential indications.

Oncternal is also developing ONCT-808, a CAR-T cell therapy targeting ROR1, showing promise in preclinical models against various hematological malignancies and solid tumors. Furthermore, ONCT-534, a dual-action androgen receptor inhibitor, is in Phase 1/2 trials for advanced prostate cancer, addressing resistance mechanisms common in patients who have relapsed after standard treatments.

Financially, Oncternal remains robust, with ongoing clinical trials supported by solid operational funding. The company maintains strategic partnerships and collaborations to foster innovation and expedite the development of its therapeutic candidates. With a focus on unmet medical needs, Oncternal Therapeutics is at the forefront of oncology research, aiming to bring new hope to patients worldwide.

Rhea-AI Summary
Oncternal Therapeutics announces dosing of first patient in Phase 1/2 study of ONCT-808 for aggressive lymphoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
-
Rhea-AI Summary

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) is hosting a Virtual Fireside Chat on April 18, 2023, at 1:30 PM EDT, focused on ROR1 CAR-T Cell Therapy for hematological malignancies and solid tumors. Moderated by Oppenheimer's Hartaj Singh, the discussion features key opinion leaders, including Dr. Michael Wang and Dr. Angela Shen, alongside Oncternal's CEO, Dr. James Breitmeyer. This event will highlight Oncternal's investigational CAR-T therapy, ONCT-808, which targets ROR1 and demonstrates preclinical success against several cancers. The company is advancing its development pipeline for treatments addressing critical unmet medical needs in oncology, particularly in aggressive B-cell lymphoma and prostate cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.71%
Tags
none
-
Rhea-AI Summary

Oncternal Therapeutics announced the closure of its zilovertamab Phase 3 study (ZILO-301) and Phase 1/2 study (CIRM-0001) due to the evolving market for BTK inhibitors. This strategic shift aims to extend the company’s cash runway into 2025, supporting further clinical development of ONCT-808 and ONCT-534. ONCT-808, targeting aggressive lymphomas, and ONCT-534, a novel AR inhibitor for mCRPC, are set to yield initial clinical data by late 2023 and mid-2024, respectively. The company's cash and equivalents are reported at $54.3 million, supporting operations through 2025. A webcast with management is scheduled for today at 5:00 PM ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-56.96%
Tags
none
Rhea-AI Summary

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the approval of an inducement award to new employee Erik S. Nelson as Head of IT. The award includes an option to purchase 64,900 shares of common stock, vesting over four years. This decision aligns with Oncternal's 2021 Employment Inducement Incentive Award Plan, aimed at attracting talent. The option price will match the stock's closing price on the grant date, April 3, 2023. The plan has been approved by independent directors per Nasdaq rules. Oncternal focuses on innovative oncology therapies targeting critical unmet medical needs in cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.05%
Tags
none
-
Rhea-AI Summary

Oncternal Therapeutics (ONCT) announced significant advancements in its oncology programs, including promising interim results from a Phase 1/2 study of zilovertamab combined with ibrutinib for MCL and CLL patients, achieving an objective response rate of 89%. The company also initiated the global Phase 3 ZILO-301 study for zilovertamab and launched the Phase 1/2 study for ONCT-808, targeting ROR1-expressing malignancies. Positive FDA feedback on the dual-action androgen receptor inhibitor ONCT-534 supports an IND filing. With $63.7 million in cash, Oncternal expects to fund operations into Q1 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.73%
Tags
-
Rhea-AI Summary

Oncternal Therapeutics (Nasdaq: ONCT) will announce its fourth quarter and full year 2022 financial results on March 9, 2023, after U.S. markets close. A webcast for stakeholders will be hosted at 2:00 p.m. PT (5:00 p.m. ET) to discuss these results alongside a comprehensive business update. Oncternal focuses on developing novel therapies for oncology treatments, particularly in hematological malignancies and prostate cancer. The company's lead program, zilovertamab, is currently undergoing global Phase 3 trials in combination with ibrutinib for mantle cell lymphoma treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
Rhea-AI Summary

Oncternal Therapeutics (Nasdaq: ONCT) has announced the grant of an inducement award to new employee Yelena Tsabur, who joins as Associate Clinical Trial Manager. The award, issued on March 1, 2023, includes an option to purchase 14,600 shares of common stock at the closing price on the grant date. This option vests over four years, with 25% vesting after the first year and the remainder vesting monthly for the next three years. The grant complies with Nasdaq's inducement rules and aims to attract talent to support Oncternal's focus on innovative oncology therapies targeting critical unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none

FAQ

What is the current stock price of Oncternal Therapeutics (ONCT)?

The current stock price of Oncternal Therapeutics (ONCT) is $0.5266 as of December 4, 2024.

What is the market cap of Oncternal Therapeutics (ONCT)?

The market cap of Oncternal Therapeutics (ONCT) is approximately 1.6M.

What does Oncternal Therapeutics specialize in?

Oncternal Therapeutics specializes in developing novel oncology therapies targeting cancers with significant unmet medical needs.

What are the key products in Oncternal's pipeline?

Key products include zilovertamab, ONCT-216, ONCT-808, and ONCT-534, targeting various malignancies and currently in different phases of clinical trials.

What is zilovertamab?

Zilovertamab is a humanized monoclonal antibody targeting ROR1, in Phase 1/2 trials for mantle cell lymphoma, chronic lymphocytic leukemia, and HER2-negative metastatic breast cancer.

What is ONCT-534?

ONCT-534 is a dual-action androgen receptor inhibitor in Phase 1/2 trials for advanced prostate cancer, addressing resistance mechanisms in relapsed patients.

How is Oncternal funded?

Oncternal has solid operational funding supporting its ongoing clinical trials, with strategic partnerships and collaborations fostering innovation.

What makes ONCT-808 unique?

ONCT-808 is a CAR-T cell therapy targeting ROR1, showing promise in preclinical models against various hematological malignancies and solid tumors.

What is the significance of ONCT-216?

ONCT-216 is a small molecule inhibitor of ETS-family oncoproteins, currently in Phase 1 trials to treat Ewing sarcoma and other potential indications.

What are the current clinical trials for Oncternal's products?

Ongoing trials include zilovertamab in Phase 1/2 for lymphoma and breast cancer, ONCT-534 in Phase 1/2 for prostate cancer, ONCT-808 in preclinical models, and ONCT-216 in Phase 1 for Ewing sarcoma.

Where can I find more information about Oncternal Therapeutics?

More information about Oncternal Therapeutics and its programs can be found on their official website at https://oncternal.com/.

How does Oncternal aim to address unmet medical needs?

Oncternal aims to address unmet medical needs by developing innovative therapies that target promising, yet untapped biological pathways implicated in cancer generation or progression.

Oncternal Therapeutics, Inc.

Nasdaq:ONCT

ONCT Rankings

ONCT Stock Data

1.56M
2.68M
9.23%
12.07%
0.48%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO